Key Takeaways Pfizer said late Monday that it has agreed to a deal to help develop and market a Chinese cancer drug across the globe.Chinese firm 3SBio is developing a drug that is in trials to treat several forms of cancer,

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more on the deal and its PFE implications.

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, manufacture and commercialise bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF),